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Abstract  
Introduction: Antiretroviral therapy has significantly reduced mortality and improved 
life expectancy of HIV-infected patients. However, the success critically depends on 
regular patient follow-up. Lost to follow-up have been emerged as legitimate threats 
to the long-term success of ART programs in resource-limited countries. However, 
no study has been done at all about incidence and predictors of lost to follow up 
among Human immunodeficiency virus positive adults particularly in the study area.  
Objective: The study was aimed at assessing incidence of lost to follow-up and it’s 
predictors among HIV-positive adults after initiation of antiretroviral therapy. 
Methods: An institution based retrospective cohort study was carried out from 
January 01/2013 to December 30/2016 among all HIV-positive adults who initiate 
ART. The data were collected by using data extraction sheet. Cumulative incidence 
function was used to estimate the probability time of lost to follow-up. Moreover, bi-
variable and multivariable sub-distribution regression model of competing risk 
regression were fitted for the potential covariates of lost to follow up. P-value ≤0.05 
was significant predictors. 
Results: Over all Cumulative incidence rate of the study was 11.6 (95% CI; 9.8 to 
13.7) per 100 adult-years follow-up time. Total follow up time was 1175 adult-years.  
At the end of the follow-up, there were 22.6% LTFU, 4.2% death and 73.2% were 
alive and transfer out. Independently significant predictors of LTFU were being male 
(aSHR=1.47:95%: CI: 1.02-3.13), being in the age of 15-24 years (aSHR=3.22:95%: 
CI: 1.65-6.28), being on WHO clinical stage IV (aSHR=1.79:95%: CI: 1.02-3.13) and 
being received isoniazid preventive therapy (IPT) (aSHR=0.11:95%: CI: 0.06-0.18). 
Conclusions: In this study the incidence of lost to follow-up was generally high in 
the first six months to one year after ART initiation. Continuous and comprehensive 
follow-up for at risk population is necessary to minimize LTFU. 
 Keywords: -lost to follow-up, cumulative incidence, competing risks regression, 
sub-distribution model, predictors, and associated factors, ART 
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1. Introduction 
1.1. Statement of the problems 
Unprecedented gains have been made in the expansion of services for ART in 
resource-constrained settings. According to WHO 2015 report from an estimated 17 
million people were accessing life-saving ART with global coverage 46% (1). Based 
on a single point estimate, there were nearly 1.2 million people living with HIV/AIDS 
in Ethiopia with incidence rate of 1.2% and 1.3% in the country level and 
Benshangul gumuz region respectively (2) by end of 2013 in Ethiopia the number of 
patients ever started  ART reached 439,301 (3)  
ART has significantly reduced mortality and improved life expectancy of HIV-infected 
patients. However, the success critically depends on regular patient follow-up(4). 
LTFU negatively impacts on the immunological benefit of ART and increases AIDS-
related morbidity, mortality, and hospitalizations(5, 6) and complicate program 
evaluation by biasing mortality estimates, and an important threat to the success of 
HIV treatment programs (7). 
LTFU in ART is an obstacle to the success of ART programs in resource- limited 
countries and have been emerged as legitimate threats to the long-term success of 
these programs. LTFU was as high as 30–50 % in one year follow up in some 
programs (8) and  18.7% particularly in Ethiopia by the end of 2012 ART(3, 9). 
understanding the reasons that underlie patient attrition and establishing more 
reliable and comparable program evaluation worldwide(10, 11)  
However, LTFU was still common and increasing in resource-limited setting 
countries including a study area, Benshangul Gumuz region, Ethiopia. In the region, 
there were the scarcity of data about lost to follow-up and there was no research 
done about incidence rate and risk factor of LTFU after ART initiation. As a result, 
this study will serve as a baseline data for program planers and policy makers 
working at various level of HIV care. Furthermore, it will serve as a baseline data for 
further researches.    
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1.2. Literature review 
1.2.1. Incidence of Lost to Follow-Up 
A systematic review study in Latin and Caribbean countries, the cumulative 
incidence of LTFU was 15.3 and  12.1 per person years for Honduras  and Mexico, 
respectively (12). Another Study conducted in South Africa incidence rate of LTFU 
was estimated to be 10.9 per 100 person-years(13). The LTFU rate was 10 per 100 
person-years ranged from 8.7 to 13.6 in Zambia (14).Besides incidence rate the 
proportion of LTFU was 15.5% in India  (15), 17.7% in Sub-Saharan African (16), 
15.6%, 27% and  36.6% in studies conducted in southeastern Nigeria(17), South 
Africa(18), and Cameron(19) respectively. 
Studies conducted in Ethiopia showed that the incidence rate was 8.2 per 100 
person years in Aksum-Northern Ethiopia(20). LTFU was 21.7%, 14.5%, 19.6% in 
Southern Ethiopia Hospitals(21), Hadiya-southern Ethiopia(22), Ethiopian public 
hospital clinic (23) respectively. 
1.2.2. Factors associated with LTFU  
1. Socio-demographic characteristics 
There were identified significant factors associated with LTFU. These include sex, 
young age, occupations, being no formal education. Sex is a significant risk factor 
LTFU. A study was done in India, Cameron, Nigeria showed that male was higher 
risk factor of LTFU  than female(15, 17, 19).  Similarly, a study conducted in 
Northern Ethiopia  showed that  male have almost 3 times higher hazard rate of 
LTFU(CI: 1.31, 5.66)(24). 
  Age was significant risk factors of the LTFU in ART. A study conducted in Nigeria 
showed that young age was risk factor of LTFU (25). Another study done South 
Africa showed that the younger age  significantly related to higher risk  of LTFU(26).  
A similarly study did in Ethiopia at different regions in  Hosanna, Mizan Aman, 
Oromia and Southern Ethiopia adolescents were at higher risk of  LTFU(21, 27-29). 
In contradiction, a study conducted in Southeastern Nigeria showed that incidence 
LTFU Loss-to-follow-up is most common among patients aged 25–34 and 35–44 
years and the lowest among those aged 15–24 years(17). 
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Educational status is significant risk factor LTFU. A study done in India showed that 
being having no education more likely risk of LTFU in ART(15). Similarly a study 
southern Ethiopia and  showed that secondary or higher educational status 
protected against LTFU(21). 
Occupation is also a significant risk factor for LTFU. A study done in Nigeria showed 
that being unemployed) was a significant risk factor to LTFU(25).similarly,  a study 
conducted in Oromia, Ethiopia being having formal education were significant 
factors(28). 
Marital status was also a significant socio-demographic variable studies conducted 
in Ethiopia survey and Oromia, Ethiopia (28, 30). 
2.2. Clinical characteristics 
CD4 count is significant risk factor for LTFU. A study done in India showed that the 
lower CD4 count was a high-risk factor for LTFU (15).A study conducted in sub-
Saharan showed that patients higher baseline CD4 counts more risk factor for LTFU 
(16). A study conducted in southern Ethiopia showed that the risk of LTFU was 
higher in patients with baseline CD4 cell counts <200 cells/mm3 (HR 1.7; 95% CIs 
1.3-2.2) compared to baseline CD4 counts ≥200 cells/mm3 Contradict(31), a study 
conducted in Ethiopia rural hospital showed that higher CD4 cell counts was 
increased hazard rate of loss to follow up(32). 
WHO stage was a significant risk factor. A study conducted India showed that the 
risk of LTFU in patients with WHO clinical stage III (HR 0.6; 95% CIs 0.44-0.9) and 
clinical stage IV (HR 0.8; 95% CIs 0.6-1.0) lower compared to clinical stage I 
(15).similarly, in Ethiopia advanced WHO stage has a significant factors for (30)  
Functional status was also a significant factor. A study conducted southern Ethiopia 
and Oromia showed that those whose bedridden functional status was increased the 
risk of LTFU(28, 31). 
TB was a significant factor. A study conducted Aksum, Northern Ethiopia showed 
that those whose who are TB positive was increased the risk of LTFU.  Additionally, 
TB prophylaxis INH was a significant independent variable in studies conducted in 
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Tigray, North-Ethiopia, Hosanna, Southern Ethiopia and Oromia, Ethiopia 
respectively(27, 28, 33). 
ART regimen was a significant variable in studies conducted in Ethiopia (30). As far 
as ART regimen change was also independent significant variable in studies 
conducted in (Hosanna and Mizan-Aman)- southern Ethiopia-and Oromia-Ethiopia 
(27, 28, 33). 
The other predictor variable that affects LTFU were adherence and nutritional status 
based on their body mass index. It was significant in studies conducted Oromia, 
Ethiopia, and Zambia respectively (27-29). 
.
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Figure 1 Conceptual Frame Work LTFU and its predictors among HIV positive adults 
on ART adapted from Literatures
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1.3. Justification  
There was a growing concern about the increasing rates of LTFU among HIV-
positive adults starting ART; that leads to further disease progression, 
transmission, and cause for mortality and morbidity. It was still common and 
increasing in resource-limited setting countries including a study area, 
Benshangul Gumuz region, Ethiopia. In the region, there was scarcity of data 
about lost to follow-up and there was no research done about incidence rate and 
risk factors of LTFU after ART initiation. As a result, this study will be an input for 
decision makers working at various level of HIV care. Furthermore, it will serve as 
a baseline data and open the floor for further researchers. 
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2. Objectives  
       2.1. General objective: 
To assess Incidence of LTFU and its Predictors among HIV-positive adults 
who were started ART from January 2012 December 30, 2016, in Paw 
General Hospital northwest Ethiopia, 2017. 
  2.2. Specific objectives:  
To determine the incidence rate of LTFU among HIV-positive adults who 
initiate ART and;  
To identify the predictors of LTFU among HIV-positive adults who initiate 
ART 
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3. Methods and Materials 
3.1. Study area and period 
The study was conducted in Pawi General Hospital from January, 01/2012 to 
December, 30/2016 which is found in Pawi woreda village 7, Metekel zone 
Benshangul Gumuz regional state, Ethiopia. Pawi is 410 Km away from the 
capital city of the region Assossa, and 570 Km away from Addis Ababa-Ethiopia. 
Apart from other services Pawi General Hospital give chronic HIV care and 
support for both pre-ART and ART service since 2005. They had 3210 patients 
ever enrolled into the care and 1760 had started ART in the hospital. Currently, 
there were 916 clients taking the service. There were 871 adults on ART service 
until December 30, 2016. 
3.2. Study design 
An institution based retrospective cohort study was carried out among HIV-
positive adult patients.   
3.3 Source population 
All HIV-positive adults who registered on ART clinic in Pawi General Hospital, 
northwest Ethiopia 
3.4. Study population  
All HIV-positive adults started ART and whose charts existed   at Pawi General 
Hospital ART clinic 
3.5. Inclusion and exclusion criteria 
3.5.1. Inclusion criteria  
 All HIV-positive adults who ever started ART at Pawi General Hospital ART clinic 
3.5.2. Exclusion criteria 
Those who had incomplete baseline data 
Those whose outcomes were not defined 
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3.6. Sample size determination and sampling procedures  
All HIV-positive adults who ever started ART in Pawi General Hospital ART clinic 
were included in the study. To check the sample size adequacy, sample size 
determination was calculated based on population proportion and predictor 
variable. 
  
             
  
 
Where w=margin of error measure of precision of estimate  
P=is incidence rate of lost to follow up  
Z   ⁄  is the value of Z from standard normal curve at 
  
 ⁄   
Based on the study conducted in Aksum Northern Ethiopia by Haile K. in 2014 
the incidence of lost to follow-up was 8.2 per 100PY(20) 
    
                  
    
=115  
Based on  predictor variables by using survival power formula with study 
conducted Mizan-Aman Hospital, southern Ethiopia, 2014(29).  
Table 1: sample size determination for study conducted among HIV positive on 
ART adults at Pawi General Hospital from January 1, 2012 to December 
30.2016.                 
Predictor variable  Assumption Hazard ratio Sample size 
CD4   Power=80% 
CI=95% 
  =log(1.75) 583 
Regimen change 
 
Power=80% 
CI=95% 
  =log(5.51) 60 
 
INH prophylaxis Power=80% 
CI=95% 
  =log(3.72) 99 
 
    
(   
 
 
     ) 
        
     and             
   
   
                            
Where Nev= is number of event (lost to follow up) 
           = log hazard ratio 
          =is the standardized effect difference of lost to follow up  
         pev= is the failure probability LTFU  
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         Z1-α/2 and Z1-β= are the reliability coefficient of lost to follow up 
           N= the numbers of participants included in the study 
Accordingly, the maximum sample size based on the above two formula was 115 
and 583. Therefore the maximum sample was 583. The actual data collected in a 
study area were 602 which was higher than the expected 
3.7. Study Variables  
3.7.1. Dependent variable 
Incidence of lost to follow-up, death as a competing event  
3.7.2. Independent variables 
Socio-demographic variables (age, sex, marital status, occupation, educational 
status) 
Baseline clinical variables (Presence of OI, CD4, WHO clinical stage, BMI, and 
functional status) 
Treatment-related variables ART adherence, Ever OI prophylaxis (INH and CPT), 
ART regimen change, Type of ART regimen) 
3.8. Operational definitions 
Lost to follow-up: Those Who were not taking an ART refill for a period of 3 
months or longer from the last attendance for refill and not yet classified as ‘dead’ 
or ‘transferred-out’ 
Time to Lost to follow-up: Was the time interval between the dates of ART 
initiation to LTFU.   
Event: was lost to follow up from ART with in the study period. 
Death: Those patients who died and confirmed by physicians. 
Transferred out: Those patients who were formally transferred out to another 
health facility 
Transfer in: Those patients who were formally transferred out from other health 
facility and entered to the hospital accordingly. 
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Censored: Those in any of the following events whichever comes first in five 
years follow-up time: If patients were transferred out to other health care center 
and if the patient were alive until the study period ends 
3.9. Data collection methods and procedures  
Data collection procedure: Data were collected based on structured data 
abstraction sheet/format from patients’ cards and registers. 
Data Source: The data for this research was secondary data recorded routinely in 
the hospital for clinical monitoring and evaluation purposes and entered into an 
electronic database and follow up medical records during the follow-up time ART. 
Patient intake form, follow up card and ART registers, as well as the electronic 
information database, were used as data sources. Other clinical charts including 
laboratory test results were also used to collect the CD4 cell counts. Health 
Management Information System card number was used to identify individual 
patient cards or their data in the electronic database. 
 Socio-demographic characteristics, baseline and follow-up clinical and laboratory 
data, and the primary outcome variable (LTFU) from ART follow-up care after 
initiation of treatment, confirmed by reviewing medical registration at the hospital, 
noted by ART adherence supporters were collected from patient cards.  
Data recording started from the date that patients started regular HIV care in the 
clinic until the end of the study to the confirmation of a final event in the study 
period were extracted by data abstraction sheet by trained nurses. 
3.10 Data quality control  
Training on the objective of the study and how to review documents as per data 
extraction sheet was given to data collectors and supervisions for one day before 
data collection was started. The data extraction sheet was pre-tested for 
consistency of understanding of tools and completeness of data for 11 charts. 
And necessary adjusted for the final data collection sheet was made. As well 3% 
random sample from data extracted was cross-checked its consistency, 
Whenever there appear incomplete, errors, and ambiguities of recording, the 
information formats were cross checked with the source card on the spot and 
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regular supervision was done. Besides there was data coding, rename, and 
clearing before analysis. 
3.11. Data processing and analysis 
Data exploration was carried out to check for any incompleteness, coding error 
and entered and cleared into EPI Info version 7. Then it was exported to Stata 
version 14.0 statistical packages for windows for further analysis. 
 Patients that were LTFU, died, who were transferred out and still in care at Pawi 
General Hospital ART clinic was identified and described. The main outcome 
variables were the incidence of LTFU and death. Patients’ data is censored at the 
time of transferred out as well on the December 30/ 2016 are considered to be 
still in care at the time of censoring.  
The patient cohort characteristics like age, CD4 count, time to LTFU and BMI 
described in terms of mean/median value and 25th & 75th percentiles and 
characteristics like sex, marital status, Occupational status, educational status, 
WHO clinical staging, OI, adherence, prophylaxis treatment, functional status, 
final outcome of study (alive, transferred out, death or LTFU) were described in 
terms percentages, frequencies (tables, graphs). Descriptive analyses of the 
continuous and categorical data describing the cohort's characteristics at 
baseline and during follow-up were also used for comparison. The outcomes of 
each patient were categorized into a status variable (0, 1, 2) as censored, lost 
and death respectively in competing risk model. 
3.12. Statistical model and Analysis 
3.12.1. Introduction  
While censoring merely obstructs us from observing the event of interest, a 
competing event prevents the event of interest from occurring altogether. 
Because competing events are distinct from standard censorings, a competing 
risks analysis requires some new methodology and some caution when 
interpreting the results from the old methodology. Based on the method of Fine 
and Gray (1999), competing-risks regression provides a useful alternative to Cox 
regression (Cox 1972) for survival data in the presence of competing risks. This 
incorrect assumption of independent censoring can lead to an inflated estimation 
of the proportion of patients who were at risk of LTFU at time t, causing 1 minus 
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Kaplan-Meier to overestimate the LTFU probability which even notified the 
difference between the two estimates graphically. 
The sub-distribution hazard for lost to follow-up is deﬁned as the probability for a 
subject to fail from cause ‘k’ in an inﬁnitesimal small time interval ∆t, given the 
subject experienced no event until time t or experienced an event other than k 
before time t. They state that the estimated coefﬁcient in the sub-distribution 
hazard model gives a consistent estimate of the so-called least false parameter  ̂ 
that can be interpreted as time-averaged sub-distribution hazard ratio. 
3.12.2. Cumulative incidence  
The 1 – KM curve overestimates the probability of LTFU at each follow-up time, 
since individuals who were dead were considered as censored. Death can be 
considered a non-random competing event whose occurrence obscures the 
occurrence of LTFU for that individual rather than prevent from seeing the event. 
Both the Kaplan-Meier survival curve (1 – KM) of lost to follow-up and the 
cumulative incidence function (CIF) in presence of competing risk were 
presented. The function CIF death(t ) denotes the probability of experiencing the 
death event before time t and before the occurrence LTFU(34). 
3.12.3. Sub-distribution hazards regression 
Competing risk regression models was used to estimate crude and adjusted sub-
hazard ratio (aSHR) and 95% CI for covariates of interest. Competing risk for 
LTFU was death. We adjusted for the effects of selected baseline and clinical 
characteristics in multivariable regression models. The variables in bi-variable 
data analysis with p-value below 0.25 was included the multivariable Sub-
distribution hazards regression model to examine the effect of different covariates 
on lost to follow up. The Fine and Gray model for the sub-distribution hazard was 
used to model cumulative incidence. Patients with the competing event was kept 
at risk and continued to contribute person time, with the remaining time at 
risk(35).  
It  took into account the informative censoring nature of the competing risk events 
which can be described as a CIF regression model and had a direct link between 
sub-distribution hazards and Can now assess covariate effects on the CIF.(36). 
Which was used sub-distribution hazard regression to estimating actual risks and 
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prognosis and the overall impact of covariates on the incidence of the lost to 
follow up(37). The model was selected by Wald statics and Bayesian information 
criteria (AIC and BIC ) (38-40) and the proportional assumption for the sub-
distribution was checked by the schoenfeld residual test.  
4.  Ethical Consideration  
Ethical clearance was obtained from the Institutional Review Board of the UOG 
institute of public health. Written informed consent was not feasible because this 
was secondary data retrieved from an electronic database and follow-up 
registration of the Hospital. Data were anonyms and handle confidentially during 
all phases of research activities. It had an open approval to use data from 
patients’ records as long as patient confidentiality was not broken. 
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5. RESULT  
5.1. Baseline socio-demographic characteristics of study participants 
Out of 720 charts 602 were included in the final analysis. From those patients, 
56.2% were females. The median age at ART initiation was 32 years with [IQR]: 
27-39). About 44.5% of participants were ages between 25-34 years were 
whereas; nearly half of study participants were married. Many of 33.32% and 
24.92% were farmers and daily labors respectively. Regarding to their 
educational status, 44.9% had no formal education whereas 36.9% had primary 
education (Table 2). 
Table 2 Baseline socio-demographic characteristics among adult HIV-positive 
adults on ART at Pawi General Hospital, Northwest Ethiopia from Jan, 2012-Dec 
30, 2016. 
Variables  Frequency(n=602) Percent (%) 
                      Age   
      15-24 years 81 13.5 
 25-34 years 268 44.5 
 35-44 years 170 28.2 
 >45 years 83 13.8 
                    Gender   
    Female 338 56.2 
 Male 264 43.8 
                    Marital status   
    Never married 112 18.6 
 Married 285 47.3 
 Divorced 146 24.3 
 Widowed 59 9.8 
                    Educational status   
 No formal education 270 44.8 
 Primary 222 36.9 
 Secondary 95 15.8 
 Territory(12+) 15 2.5 
                    Occupation   
     Daily labor          150 24.9 
 Farmer 200 33.2 
 Merchant 67 11.1 
 Government employee 48 8.0 
 Self-employee 42 7.0 
 Student 31 5.2 
 House wife 64 10.6 
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5.2. Baseline clinical status of Adult HIV-positive on ART 
Nearly half of patients were eligible for ART by WHO clinical stage and TLC while 
48% of them were by CD4 cell count criteria. The mean baseline CD4 cell count 
was 217 (IQR: 119-341) cells. Regarding nutritional status, 42.4% of participants 
were malnourished. More than half 54% of the study participants have initiated 
ART at WHO stage III. Cotrimoxazole Preventive Therapy (CPT) and isoniazid 
Preventive Therapy (IPT) for TB were given for 69.4% and 56.2% respectively.  
Nearly two third of the patients started ART treatment with TDF-3TC-EFV and 6% 
of the patients were substituted to another regimen within first line, and 2% 
switched to the second line. Over 97% of the participant’s drug adherence was 
good (Table 3). Majority of study participants were working functional status. 
More than one-fifth of participants had OI of which 51.8% had TB followed by 
bacterial pneumonia 38.62% (Figure 2). 
 
Figure 2 prevalence of opportunistic infection among HIV-positive adults on ART 
at Pawi General Hospital, northwest Ethiopia from January 1, 2012 to Dec, 2016 
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Table 3 Base line clinical characteristics of among HIV-positive adult on ART at 
Pawi General Hospital, northwest Ethiopia from Jan 1, 2012 to Dec, 30 2016 
                Variables    Frequency(N=602) Percent (%) 
                          IPT 
  
 Not received 262 43.8 
Received 340 56.2 
                         CPT   
  Not receiving 184 30.6 
Receiving 418 69.4 
                Opportunistic  infection   
 No OI 469 77.9 
Have OI 133 22.1 
                  WHO Clinical stage   
 Stage I 55 9.1 
Stage II 172 28.6 
Stage III 325 54.0 
Stage IV 50 8.3 
                   ART regimen   
 1c(AZT-3TC-NVP) 97 16.1 
1d(AZT-3TC-EFV) 26 4.3 
1e(TDF-3TC-EFV) 410 68.1 
1f(TDF-3TC-NVP) 69 11.5 
                    Functional status   
 Working 444 73.8 
Ambulatory 99 16.4 
Bedridden 59 9.8 
                     Adherence   
 Good 585 97.2 
Fair 12 2.0 
Poor 5 0.8 
                   Regimen change   
 NO 555 92.2 
YES First line 36 6.0 
Second line 11 1.8 
                    Nutritional status (BMI)   
 Normal 347 57.6 
Malnourished 255 42.4 
                    CD4 cell count(cell/mm3)   
 <=100 cell/m3 119 19.8 
 101-200 cell/m3 141 23.4 
 201-350 cell/m3 194 32.2 
 >350 cell/m3 148 24.6 
AZT-Zidovudine, 3TC-Lamivudine, NVP-Nevirapine,  
EFV-Efavirenz, TDF-Tenofovier 
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5.3. Incidence of lost to follow-up of HIV-positive adults  
Among 602 HIV-positive adults on ART, a total follow-up time was 1175 adult-
years observation with an incidence rate of 11.6 (95% CI 9.8 to 13.7) per 100 
adult-years LTFU. The study subject followed for a minimum of three months and 
maximum of 60 months after initiated ART with median follow-up time of LTFU 
was 18 months. The median survival time of male is shorter than female which 
was 15 and 23 months respectively. Nearly half of the study subjects were lost to 
follow -up within the first six months and 72.8% were lost before a year. Death 
was 25(4.2%) and the remaining 73.3% were censored. The cumulative 
probabilities of lost to follow-up at 6, 12 and 24 months were 0.09, 0.17, 0.25 
respectively and 0.29 within the time interval 36-60 months.  
LTFU was used as the event of interest and death was considered as competing 
risk. So to illustrate the differences in cumulative probability of LTFU estimates 
given by two estimators (1 minus Kaplan-Meier and cumulative incidence), in the 
presence of death as a competing risk were compared (Figure 3). 
 
Figure 3 Kaplan-Meier and the CI curves among HIV-positive adults on ART at 
Pawi General Hospital, northwest Ethiopia from Jan, 2012 to Dec 2016.  
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5.4. Predictors of LTFU among HIV-positive adults  
Test for equality of the incidence curves for categorical predictor variables was 
performed by using cumulative incidence. These of exploratory variables include 
age category, sex, WHO clinical stage and isoniazid prophylaxis, were 
significantly associated with LTFU of HIV-positive adults.  
Based on the findings from the bivariate fine and gray/sub-distribution/ model 
analysis; age category, sex male, cotrimoxazole preventive therapy, WHO clinical 
stage, isoniazid Preventive Therapy, CD4 cell count, body mass index, drug 
regimen, opportunistic infection and functional status were predictors of LTFU. All 
ten covariates were fitted to the multivariable fine and gray model. Consequently, 
in multivariable sub-distribution sex, age category 15-24 years, not on IPT and, 
WHO clinical stage was significantly associated with LTFU of HIV-positive adults.  
Age: Incidence rate of LTFU among age category 15-24 years, 25-34 years, 35-
44 years and above 45 years were 256,101,122 and 61 per 1000 person- years 
respectively (Figure 4). 
 
 Figure 4: Cumulative incidence curve by age category among HIV-positive adult 
on ART at Pawi General Hospital, northwest Ethiopia from January 1, 2012 to 
December 30, 2016 
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Sex: Incidence rate of lost to follow up based on their sex were 90 and 123 per 
1000 person years respectively.  
 
 
Figure 5: Cumulative incidence curve by sex among HIV-positive adult on ART at 
Pawi General Hospital, northwest Ethiopia from January 1, 2012 to December 30, 
2016 
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WHO clinical stage: Incidence rate of lost to follow up among WHO clinical stage 
I/II, III and IV were 80, 123 and 249 per 1000 person years respectively.  
 
 
 
Figure 6: Cumulative incidence curve by WHO clinical stages among HIV-positive 
adult on ART at Pawi General Hospital, northwest Ethiopia from January 1, 2012 
to December 30, 2016 
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Isoniazid Preventive Therapy prophylaxis :The incidence rate of LTFU up among 
clients who have received IPT were 309 per 1000 person years while not 
received INH was 26 per 1000 person years respectively.  
 
Figure 7: Cumulative incidence curve by isoniazid Preventive Therapy among 
HIV positive adults on ART at Pawi General Hospital, northwest Ethiopia from 
Jan, 2012 to Dec 30, 2016 
Accordingly, being male adults increased the sub-hazard ratio of LTFU by 47% 
as compared to female adults   (aSHR=1.47:95%: CI: 1.02-3.13). Adults whose 
age category between 15 and  years increased the sub-hazard ratio of LTFU by 
3.22 times as compared to those whose age category were above 45 
years(aSHR=3.22:95%: CI:1.65-6.28). Those adults who were on WHO clinical 
stage IV increased the sub-hazard ratio of LTFU by 79%  as compared to those 
adults with stage I and II (aSHR=1.79:95%: CI:1.02-3.13). Being on IPT lowered 
sub-distribution ratio for LTFU by 89% as compared to its counter parts 
(aSHR=0.11:95%: CI: 0.06-0.18). (Table 4) 
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Table 4: Multivariable competing risk regression analysis for predictors of LTFU among HIV-positive Adults at Pawi 
General Hospital, northwest Ethiopia, and January 1, 2012 to December 30, 2016 
Variable                        Survival status   
Time  Lost Death Censored cSHR:[95%CI] aSHR:[95% CI] P-value 
Age        
15-24 years 30 2 49 3.32[1.70-6.48] 3.22[1.65-6.28] 0.001* 
25-34 years 53 13 202 1.46[0.78-2.72] 1.57[0.85-2.91] 0.152 
35-45 years 41 5      124 1.82[0.90-3.46] 1.87[0.98-3.57] 0.058 
>45 years 12 5 66 1 1  
Sex        
Female 63 12 262 1 1  
Male  73 13 179 1.60[1.14-2.23] 1.47[1.02-2.1] 0.038* 
Nutritional status        
Normal  69 10 268 1 1  
Malnourished  67 15 173 1.38[0.99-1.93] 1.38[0.95-2.01] 0.095 
WHO clinical stage       
Stage (I/II) 36 5 186 1 1  
Stage III 79 13 232 1.55[1.05-2.29] 1.24[0.83-1.83] 0.292 
Stage IV 21 7 23 2.77[1.62-4.76] 1.79[1.02-3.13] 0.042* 
Functional status        
Working  85 6 353 1 1  
Ambulatory  33 12 54 1.74[1.17-2.60] 1.03[0.66-1.60] 0.900 
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Table 4 (Continued) 
Bedridden  18 7 34 1.46[0.89-2.37] 1.13[0.67-1.90] 0.649 
Isoniazid        
Not received  115 22 125 1 1  
Received  21 3 316 0.11[0.07-0.17] 0.11[0.07-0.18] <0.001* 
CPT        
Not received  46 12 126 1 1  
Received  90 13 315 0.79[0.56-1.12] 0.98[0.66-1.47] 0.938 
CD4 cell count       
<=100 cell/m3 30 17 72 0.91[0.56-1.46] 0.71[0.40-1.25] 0.232 
101-200 cell/m3 30 4 107 0.73[0.46-1.17] 0.83[0.50-1.39] 0.479 
201-350 cell/m3 38 1 155 0.67[0.43-1.05] 0.91[0.56-1.49] 0.712 
>350 cell/m3 38 3 107 1 1  
Opportunistic infection        
No  93 13 363 1 1  
Yes  43 12 77 1.58[1.12-2.23] 0.87[0.61-1.26] 0.470 
Regimen        
1c(AZT-3TC-NVP) 20 2 73 1 1  
1d(AZT-3TC-EFV) 3 0 23 0.58[0.18-1.89] 0.49[0.14-1.74] 0.272 
1e(TDF-3TC-EFV) 97 17 295 1.37[0.85-2.21] 1.38[0.83-2.29] 0.216 
1f(TDF-3TC-NVP) 16 6 48 1.09[0.58-2.05] 1.28[0.66-2.49] 0.465 
*significant covariates, cSHR- crude Sub-Hazard Ratio, aSHR-adjusted Sub-Hazard Ratio
25 
 
6. Discussion  
This retrospective follow up study aim to assess the incidence of lost to follow up 
and its predictors among HIV positive adults after initiating ART. Several studies 
have shown that LTFU poses challenges to the successful implementation of ART 
programs in low and medium resource settings (8). LTFU can interrupt treatment, 
resulting in further disease progression, continued HIV transmission, negatively 
impacts on the immunological benefit of ART and increases AIDS-related morbidity, 
mortality, hospitalizations(5, 7, 8) and result in serious consequences, such as 
discontinuation of treatment, drug toxicity, treatment failure, and drug resistance(6)  
In this study, the incidence rate was estimated to be 11.6 per 100 adult-years. Which 
was consistent  with studies done in Lain and Caribbean countries with an incidence 
rate of (12.1-15.3)/100 person-year(12) and study done in South Africa(10.9/100 
person-year)(13).On the other hand  incidence rate in the current study was higher 
than studies in Zambia(8.7/100 person-year)(14) and Aksum, Northern-Ethiopia (8.2 
per 100 person-years)(20). This variation might be explained by study settings 
difference, transfer to different health institution without prior information to their 
original health institution where they registered initially for proper recording and 
transfer out as can be supported with 19% transfer out rate findings, health seeking 
behavior and late initiation of the community as supported by the results delayed 
initiation of ART at advanced WHO clinical stage III and IV.  
In addition to the incidence rate, proportion of  LTFU for those studies not reported in 
person year observation was 22.6% which was lower than studies conducted in 
Cameroon 36.6%(19) and South Africa 27.6%(18), and consistent with studies 
conducted in southern nations nationality and people- Ethiopia 21.7%(21).on the 
other hand  this finding  also higher than studies done in India (15.5%), Sub-Saharan 
Africa (17.7%), Nigeria (15.6%), Hadiyia-southern Ethiopia 14.5%  and Ethiopian 
public hospitals 19.6% (15-17, 22, 23) . This might be explained by travelling costs 
to the clinic since the study area were sparsely populated with limited-infrastructure 
directly or indirectly related to the study area were under developing region of 
Ethiopia with limited-resource and health service 
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As could be noted from the findings of multivariable findings in subdistribution 
hazard regression, in analyzing competing risks data: gender (male), age category 
(15-24 years), not on INH prophylaxis and WHO clinical stage IV were independent 
predictors of LTFU at 5% level of significance 
Gender difference was detected independent predictors of LTFU, that male was 
increased the sub-hazard ratio of LTFU by 47% as compared to female. This finding 
was supported by studies conducted in India, Nigeria, Cameron and Aksum-Ethiopia 
(15, 17, 19, 24). This might be high mobility as far as most of the study participants 
male were daily labor and farmer, so they might haven’t stable area they live.  
Age category at 15-24(adolescence) was anther independent predictors of LTFU 
that Adolescents had 3.22 times higher sub-hazard risk of LTFU as compared to 
those who were above the age of 45 years. This finding was consistent with studies 
conducted in Southern Nigeria, South Africa, and southern Ethiopia (21, 25-28). This 
might be adolescent’s particularly disobedient, showed immaturity in analytical 
thinking, and there may have been faced particular challenges associated with 
puberty. But this finding contradicted in a study conducted in Nigeria (17)that 
younger age groups were a lower risk of LTFU. 
According, WHO clinical stage was independent predictors of LTFU. Those HIV-
positive adults who were advanced clinical stage IV were 79% higher sub-hazard 
risk of LTFU as compared to those whose WHO clinical stage I/II. This evidence was 
supported by studies conducted in India and Oromia-Ethiopia (15, 30).They are also 
more likely to die due to ART side effects within the first 6 months of ART initiation. 
This was because another study indicated that half of LTFU  in ART was due to 
death Nigeria (17).This study also showed that more than half of participant was in 
stage III and IV. 
Moreover, Isoniazid Preventive Therapy prophylaxis was another predictors of 
LTFU; those who were received INH were lower the sub-hazard ratio of LTFU by 
89% as compared to those who were not received IPT. This result was in line with 
studies conducted in southern Ethiopia, Northern Ethiopia and Oromia-Ethiopia (27, 
28, 33). Isoniazid Preventive Therapy prophylaxis may have been impacted directly 
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or indirectly on LTFU which was recommended by national ART guideline to prevent 
the occurrence of TB-co-infection which was one of the causes of morbidity and 
mortality. 
7. Limitation of the study 
Since this is a retrospective cohort study, the data were already collected from 
patient’s card which resulted incomplete information. As a result, unable to include 
important predictors like viral load and micronutrient deficiency (hemoglobin) and 
clinical factors (like side effects) were not well documented. 
Strength of study considering death as a competing event improves the quality of 
estimation that avoided overestimation of one minus Kaplan-Meier by using 
cumulative incidence. 
8. Conclusion  
The higher LTFU incidence rate has been observed and more than half of LTFU was 
in the first six and twelve months.  
Being male, age between 15-24 years, WHO clinical stage IV and not on INH 
prophylaxes were major independent baseline patient predictor’s that affect 
incidence of LTFU. 
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9. Recommendation 
For health care provider 
 Close follow up of HIV positive adults on ART particularly during the first 6 
month and one year is important to decrease lost to follow up  
 Isoniazid preventive therapy prophylaxis increases the survival of patients, so 
better to encourage providing INH at the start of ART.  
 Better to encourage Health education and promotion on early initiation before 
advanced WHO clinical stage  
 Better to give especial emphasis on counseling, continuance follow-up and 
tracking for adults between age of 15 and 24 years. 
For NGOs 
 Strengthen monitoring and evolution at grass root level for the effectiveness 
of ART outcomes, especially on documentation system, provision of 
supplementary drugs for ART services like CPT and INH  
For researchers  
 Since LTFU incidence rate was high, better to find out true outcome of lost to 
follow-up  
 The cumulative incidence will better be used in the presence of competing 
event that obscures the event of interest from happening  
 Better to retrospective study was a full of inevitable incomplete information, so 
better to conduct   prospective cohort study design to address behavioral 
factors  
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 ANNEX 
Annex- Information Sheet 
Title Of The Research Project: To assess lost to follow up and its predictors among 
adult people living with HIV who initiate ART in pawi General Hospital, northwest 
Ethiopia 
Name of Principal Investigator: Moges Agazhe 
Name of the Organization: Institute of Public Health, College of Medicine and Health 
Sciences, University of Gondar 
Name of the Sponsor:  self   
Introduction: This  information  sheet  was  prepared For Pawi General Hospital 
administration and ART coordinating office .The aim of this information sheet was to 
make clear the above body about the research project, data collection procedure 
and to get permission to undertake the research. 
Purpose of research: To assess lost to follow up and its predictors among adult 
people living with HIV who initiate ART in pawi General Hospital, northwest Ethiopia 
Procedure: To achieve the above objective all HIV positive adults starting from 
January 2012 to December 2016 will be included in the study. 
Risk and discomfort: By participating in this research there was no risk encountered 
to whom document is reviewed for data extraction. 
Benefits: the research has no direct benefit for the patient whose record was 
reviewed but the indirect benefit for the participant and all others had a great impact 
for planning. 
Confidentiality: The information collected from this research project was kept 
confidential and information about data that were collected by this study was stored 
without names, In addition, it was not revealed to anyone except the principal 
investigator and was kept locked with key and the data were collected by trained 
nurses who work in the ART clinic. 
Incentives: There was no any incentive/ payment provided to take part in this project. 
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Persons to contact: If you have any question about the research project you can 
contact the advisors and principal investigators via the following address.  
1. Mr. Tadesse Awoke(Associated professor ,PHD Scholar) University of Gondar, 
college of medicine and health science, institute of public health (advisor) 
                          Tel: +251910173308            
                           Email:  tawoke7@gmail.com 
2. Mr. Kindie Fentahun (BSc, MSc in biostatistics)University of Gondar, college of 
medicine and health science, institute of public health (advisor) 
                          Tel: +251928436726          
                           Email :mkindief@gmail.com 
3. Moges Agazhe (BSc) university of Gondar, college of medicine and health science 
department of master of public health in biostatistics (principal investigator) 
      Tel: +251921675847/975211793       
       Email agazhemoges@gmail.com 
Permission: lastly you are kindly requested to permit and forward your permission to 
the concerned body in your institution to get the data clerk and other responsible 
body. 
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Annex 2- Data abstraction sheet/Check list  
Data collection format    
This checklist was prepared for the collection of socio-demographic, clinical, treatment and outcome related information that 
are important for the assessment of LTFU and predictors LTFU who initiate antiretroviral therapy in Pawi general Hospital. All 
this information was retrieved from the clients ART and pre-ART registration book and from individual patient card without 
mentioning the name of clients. This information was collected by health care providers (BSc nurses) possibly working in the 
ART clinic of the hospitals. 
  Contact Information  
Mr. Tadesse Awoke    cell phone +251910173308(Advisor) 
Mr. Kindie Fentahun cell phone +251928436726 (Advisor) 
Moges Agazhe      cell phone +251921675847(investigator) 
Part I: base line data  (All adult patients who initiated ART in the year 2012-2016) 
S.No Variables  Categories       
101.  MRN number       
102.  Age  _________yrs.     
103.  Gender    1 Female            2 Male     
104.  Marital status  1. Never 
married               
2. Married              3.Divorced        4. Widowed       
105.  Education  1. No formal education 2. primary   3 .Secondary 4 .Tertiary 
106.  Occupation  1. sex worker 
2. driver 
3. daily labor 
4. merchant   
5. Farmer. 
 6. Government 
7.  self-employed 
8. others(s)       
107.  Opportunistic 
infection  
1. No  
2.  BP 
3. PTP 
4. EPTB 
5. Rush 
6.  Diarrhea 
7. PCP   
8. Ulcer 
9. .Other(s) ------- 
108.  Past TB status  1.  Yes               2. No     
109.  ART start date  ______/______/______dd/mm/yyyy     
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110.  Base Weight  ________kgm      
111.  Base CD4 counts  _______________cell/µl     
112.  Base WHO 
clinical stage  
1.  Stage I       2. Stage II        3. Stage III       4. Stage IV   
113.  Base Functional 
status  
1.  Working         2.   Ambulatory     3. 
Bedridden 
  
114.  Original regimen  1. 1a  
2. 1b   
3. 1c 
4. 1d      
5. 1e 
6. 1f     
7. 1g 
8. 1h 
  
115.  ART Eligibility 
criteria   
1. Clinical stage 2. CD4 count 3. TLC 4. Transfer in   
Part III: Follow-up variables  
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Final outcome 1.  Alive 2. Death 3. Lost to follow up 4. Transfer out 
         Collected by: Name ____________________________ Signature ____________Date ________________ 
         Supervised by: Name ___________________________ Signature ____________Date __________
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